Board of Directors

Mats Blom

Chairman

BA, Business Administration and Economics, University of Lund and MBA, IESE University of Navarra, Barcelona, Spain

Chairman since: May 2024

Member of the Board since: April 2021
Number of shares in Egetis: 3,134,762

Born 1965

Other assignments: Currently serves as the CFO of NorthSea Therapeutics, Amsterdam, the Netherlands. Board member of Hansa Biopharma AB, Altamira Therapeutics Ltd and Pephexia Therapeutics ApS.

Previous experience: He has served as CFO of Zealand Pharma A/B, a biotechnology company dual listed at Nasdaq in New York and Copenhagen, and Swedish Orphan International, an orphan drug company acquired by BioVitrum in 2009. In addition, Mats has been CFO at Modus Therapeutics, Active Biotech AB and Anoto Group AB. He has also served as a management consultant at Gemini Consulting and Ernst & Young.

Independent in relation to the Company’s major shareholders and the Company and its management.

Gunilla Osswald

Board Member

Pharmacist and PhD in biopharmacy and pharmacokinetics at Uppsala University, Sweden

Member of the Board since: 2017
Number of shares in Egetis: 40,000

Born: 1961

Other current assignments: President and Chief Executive Officer of BioArctic AB. Board member of SpineMedical AB and deputy board member of LPB Sweden AB

Previous appointments: Board member of SP Process Development AB, SpineMedical Sverige AB and LPB Sweden Holding AB.

Independent in relation to the Company’s major shareholders and the Company and its management.

Elisabeth Svanberg

Board Member

MD and PhD from the University of Gothenburg, Sweden.

Member of the Board since: 2017
Number of shares in Egetis: 37,676

Born 1961

Other appointments: Currently serves as associate professor of surgery and is serving as Chief Development Officer at Ixaltis SA since 2016 and Chief Medical Officer at Kuste Biopharma since 2020. Board member of Galapagos NV, Amolyt Pharma SAS, LEO Pharma A/S and EPICS Therapeutics.

Previous appointments: Board member of the Swedish American Chamber of Commerce New York. Head of the Established Products Group at Janssen Pharmaceuticals 2014–2016. Leading the development of a novel diabetes medicine at Bristol Myers Squibb (BMS) in the US. Head of Medical Affairs for the Intercontinental region 2011–2014.

Independent in relation to the Company’s major shareholders and the Company and its management.

Behshad Sheldon

Board Member

BS in neuroscience from University of Rochester.

Member of the Board since: 2023
Number of shares in Egetis: 0

Born: 1963

Other current assignments: Board Member, Camurus AB; Chairman of the Board of FORCE (Female Opioid Research and Clinical Experts) in Princeton, New Jersey; Board Member, Maxona Pharmaceuticals, Philadelphia, Pennsylvania; EVP & Managing Director, Biotech Value Advisors.

Previous appointments: President & CEO of Braeburn Pharmaceuticals until 2017. She has also extensive global and US experience from various senior positions in international pharmaceutical companies, including Smithkline Beecham, Bristol-Myers Squibb and Otsuka Pharmaceuticals.

Independent in relation to the Company’s major shareholders and the Company and its management.

Margarida Duarte

Board Member

BS in Pharmaceutical Sciences from Universidade de Lisboa and an Executive Master’s degree in Medical Marketing Management from Instituto Universitário de Lisboa.

Member of the Board since: 2025
Number of shares in Egetis: 0

Born: 1976

Other current assignments: Executive Vice President, Global Chief Commercial Officer, Deciphera Pharmaceuticals.

Previous appointments: Vice President, Head of Commercial Canada, Europe and Middle East and Africa for Alnylam Pharmaceuticals until 2021, launching Alnylam’s first products in rare disease. Ms. Duarte also has extensive global experience from various senior commercial positions in international pharmaceutical companies, including STEPSTONE Pharma, Exelixis, Onyx Pharmaceuticals and Amgen, with a focus in oncology and hematology and rare diseases.

Independent in relation to the Company’s major shareholders and the Company and its management.